HABA Laboratories, Inc.

As of March 31, 2026, HABA Laboratories, Inc. carries a market capitalization of 6.43B, placing it among publicly traded companies globally. Its enterprise value stands at 1.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HABA Laboratories, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, HABA Laboratories, Inc. has 3.78M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, HABA Laboratories, Inc. maintains a current ratio of 4.17, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 23, 2026, HABA Laboratories, Inc.'s stock has gained approximately 0.36% over the past 52 weeks. The 50-day moving average sits at 1,713.94, while the 200-day moving average is 1,729.49.

As of March 31, 2026, HABA Laboratories, Inc. holds 5.78B in cash and equivalents against 1.19B in total debt, resulting in a net debt position of -4.60B. Total book value stands at 9.54B, with working capital of 7.43B providing operational flexibility.